Skip to main content
Advanced Technical IVT

MOG antibodies

Also written as: MOG — myelin oligodendrocyte glycoprotein

Antibodies targeting myelin oligodendrocyte glycoprotein, associated with a distinct demyelinating syndrome.

Full Definition

Myelin oligodendrocyte glycoprotein (MOG) antibodies are autoantibodies that target MOG, a protein found on the outer surface of myelin sheaths. MOG antibody-associated disease (MOGAD) is now recognized as a distinct clinical entity separate from multiple sclerosis and neuromyelitis optica. Patients typically present with optic neuritis, transverse myelitis, or acute disseminated encephalomyelitis-like symptoms. Unlike AQP4-NMOSD, MOG antibody disease often has a more favorable prognosis and may be monophasic, though relapses can occur. Testing requires cell-based assays for accuracy.

Usage

Usage note: Distinguish from MOG protein itself; specify testing methodology when discussing results.

In Context

  • "The patient tested positive for MOG antibodies using cell-based assays." — Laboratory report
  • "MOG antibody-associated disease often presents with bilateral optic neuritis." — Case report

Also known as

anti-MOG antibodies MOG-IgG

Don't confuse with

AQP4 antibodies MBP antibodies

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON